Refractory precursor T-lymphoblastic lymphoma/leukemia

This study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…

This early study tests a new treatment called U69, which uses a patient's own immune cells modified to find and attack cancer cells in T-cell leukemia or lymphoma that has come back or not responded to other treatments. About 12 to 18 people aged 15 to 75 will receive the therapy…

This early-stage trial tests a new type of cell therapy for children and young adults up to age 21 with a form of leukemia (CD19-positive) that has returned or not responded to treatment. The therapy uses immune cells from a family donor that are engineered in a lab to recognize …

This study tests a new treatment called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) that has come back or not responded to other treatments. Participants receive one infusion of CTD402 and are monitored for safety and how w…

This early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to c…

This phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…

This study is testing whether a personalized cell therapy called MB-CART19.1 can be manufactured right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own i…

This early-phase study tests a new treatment called BEAM-201 for children and young adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments. BEAM-201 uses donor-derived immune cells that are engin…

This Phase 2 trial tests a single infusion of PA3-17, a CAR-T cell therapy that targets CD7 on cancer cells, in 100 adults with relapsed or refractory T-lymphoblastic leukemia or lymphoma. Participants receive the treatment after a short chemotherapy prep, and researchers will mo…

This early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for children, adolescents, and young adults with high-risk blood cancers like MDS, AML, and ALL. About 30 participants will receive different combinations of chemot…

This study tests two approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a sequence of two types of CAR T-cells (targeting CD19 and CD22), while the other gets one type of CAR T-cell followed by a stem ce…

This study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…

This early-stage trial is testing a new type of immune cell therapy called supCD7 CART cells in 12 adults with relapsed or refractory CD7-positive blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia). The cells are designed to target and kill cancer cells that carry…

This early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …

This study tests a new combination of drugs for children and young adults whose leukemia or lymphoma has returned or not responded to treatment. The drugs include trametinib (a targeted therapy) plus standard chemotherapy. The goal is to find the safest dose and see if the combin…

This trial tests a combination of dasatinib, venetoclax, and chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The study has two phases: first to find the safest dose, then to see how well it …

This study tests a combination of two targeted drugs (ruxolitinib and venetoclax) plus standard chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find the safest dose and see how many patie…

This early-phase study is testing a new type of immune cell therapy called universal CD7 CAR-T (uCD7 CART) in people with relapsed or refractory acute myeloid leukemia (AML) or T-cell leukemia/lymphoma. The cells are designed to target and kill cancer cells that carry the CD7 pro…